Gangji D, Juvent M, Niset G, Wathieu M, Degreve M, Bellens R, Poortmans J, Degre S, Fitzsimons T J, Herchuelz A
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):29S-35S. doi: 10.1111/j.1365-2125.1984.tb02425.x.
The influence of chronic therapy with nifedipine on the pharmacokinetics of propranolol 80 mg twice daily, metoprolol 100 mg twice daily and atenolol 100 mg once daily was investigated in eight healthy volunteers. Nifedipine 10 mg three times daily did not affect the pharmacokinetics of metoprolol and atenolol whereas nifedipine shortened the time to peak plasma concentration for propranolol by about 1 h. Propranolol, metoprolol and atenolol provoked comparable decreases in heart rate measured at rest and during exercise. The beta-adrenoceptor blocking properties of propranolol, metoprolol and atenolol were not affected by concomitant therapy with nifedipine. The present study did not show significant pharmacokinetic and pharmacodynamic interactions between nifedipine and lipophilic beta-adrenoceptor blockers.
在八名健康志愿者中研究了硝苯地平长期治疗对每日两次服用80毫克普萘洛尔、每日两次服用100毫克美托洛尔以及每日一次服用100毫克阿替洛尔药代动力学的影响。每日三次服用10毫克硝苯地平对美托洛尔和阿替洛尔的药代动力学没有影响，而硝苯地平使普萘洛尔的血浆峰浓度时间缩短了约1小时。普萘洛尔、美托洛尔和阿替洛尔在静息和运动时测得的心率下降程度相当。普萘洛尔、美托洛尔和阿替洛尔的β-肾上腺素能受体阻断特性不受与硝苯地平联合治疗的影响。本研究未显示硝苯地平和脂溶性β-肾上腺素能受体阻滞剂之间存在显著的药代动力学和药效学相互作用。
